<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02171234</url>
  </required_header>
  <id_info>
    <org_study_id>BIA-2093-102</org_study_id>
    <nct_id>NCT02171234</nct_id>
  </id_info>
  <brief_title>A Double-blind, Randomised, Placebo-controlled, Rising Multiple Dose Study to Investigate the Safety, Tolerability, Steady State Pharmacokinetic Profile and CNS Effects of BIA 2-093</brief_title>
  <official_title>A Double-blind, Randomised, Placebo-controlled, Rising Multiple Dose Study to Investigate the Safety, Tolerability, Steady State Pharmacokinetic Profile and CNS Effects of BIA 2-093, in Young Healthy Male Volunteers.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bial - Portela C S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bial - Portela C S.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the safety and tolerability of multiple dose
      regimens of BIA 2-093 in healthy young male volunteers
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Single centre, Phase I, double-blind, randomised, placebo-controlled study investigating 4
      multiple rising oral doses of BIA 2-093 in 4 groups of 8 young healthy male subjects. Within
      each group, 2 subjects were randomised to receive placebo and the remaining 6 subjects to
      receive BIA 2-093. No subject was a member of more than one group. The dose regimens
      investigated were: 200 mg b.i.d.(twice daily), 400 mg o.d.(once daily; this was changed from
      400 mg b.i.d. in protocol amendment 1, on the basis of interim pharmacokinetic analysis of
      Group 1 data), 800 mg o.d, and 1200 mg o.d. BIA 2-093/placebo was administered orally once
      daily on Days 1-8, or twice a day (at 12-hour intervals) on Days 1-7 with a final dose in the
      morning of Day 8. The multiple dose regimens were to be investigated in ascending order.
      Progression to each higher dose level was only to occur if the previous dose level was deemed
      by the investigator and the sponsor to be safe and well tolerated.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2001</start_date>
  <completion_date type="Actual">June 2001</completion_date>
  <primary_completion_date type="Actual">June 2001</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total Number of Adverse Events</measure>
    <time_frame>up to 20 weeks</time_frame>
    <description>Total Number of Adverse Events.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>Day 1 and Day 8</time_frame>
    <description>Cmax - Maximum observed plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-τ</measure>
    <time_frame>Day 1 - pre-dose, 30, 60, 90, 120, 180 minutes, 4, 6, 7, 8, 12, hours post final dose Day 8 - pre-dose, 30, 60, 90, 120, 180 minutes, 4, 6, 7, 8, 12, 24, 36, 48 and 72 hours post final dose</time_frame>
    <description>AUC0-τ - Area under the plasma concentration time curve to last measurable time point
Day 1 - pre-dose, 30, 60, 90, 120, 180 minutes, 4, 6, 7, 8, 12, hours post final dose Day 8 - pre-dose, 30, 60, 90, 120, 180 minutes, 4, 6, 7, 8, 12, 24, 36, 48 and 72 hours post final dose</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Epilepsy</condition>
  <arm_group>
    <arm_group_label>Group 1- 200 mg b.i.d. (twice daily)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BIA 2-093 200mg with 200 ml potable water. Identical placebo administered as oral tablets.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 - 400 mg b.i.d.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BIA 2-093 200mg with 200 ml potable water. Identical placebo administered as oral tablets.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3- 800 mg o.d. (once daily)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BIA 2-093 200mg with 200 ml potable water. Identical placebo administered as oral tablets.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4 - either 800 mg b.i.d or 1200 mg o.d.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BIA 2-093 200mg with 200 ml potable water. Identical placebo administered as oral tablets.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Group 1- 200 mg b.i.d. (twice daily)</arm_group_label>
    <arm_group_label>Group 2 - 400 mg b.i.d.</arm_group_label>
    <arm_group_label>Group 3- 800 mg o.d. (once daily)</arm_group_label>
    <arm_group_label>Group 4 - either 800 mg b.i.d or 1200 mg o.d.</arm_group_label>
    <other_name>PLC, Placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIA 2-093</intervention_name>
    <arm_group_label>Group 1- 200 mg b.i.d. (twice daily)</arm_group_label>
    <arm_group_label>Group 2 - 400 mg b.i.d.</arm_group_label>
    <arm_group_label>Group 3- 800 mg o.d. (once daily)</arm_group_label>
    <arm_group_label>Group 4 - either 800 mg b.i.d or 1200 mg o.d.</arm_group_label>
    <other_name>ESL, Eslicarbazepine acetate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  Inclusion Criteria:

          -  Adult males aged 18-45 years, with a body mass index (BMI) of 19-28 kg/m2.

          -  Subjects who were healthy as determined by pre-study medical history, physical
             examination, 12-lead ECG and EEG.

          -  Subjects who had clinical laboratory tests acceptable to the investigator.

          -  Subjects who were negative for HbsAg, anti-HCV and HIV I and II tests at screening.

          -  Subjects who were negative for drugs of abuse and alcohol tests at screening and
             admission.

          -  Subjects who were non-smokers or previous smokers who had not smoked for at least 6
             months.

          -  Subjects who were able and willing to give written informed consent.

          -  Exclusion Criteria:

          -  Subjects who did not conform to the above inclusion criteria.

          -  Subjects who had a clinically relevant history or presence of respiratory,
             gastrointestinal, renal, hepatic, haematological, lymphatic, neurological,
             cardiovascular, psychiatric, musculoskeletal, genitourinary, immunological,
             dermatological, connective tissue diseases or disorders.

          -  Subjects who had a clinically relevant surgical history.

          -  Subjects who had a clinically relevant family history.

          -  Subjects who had a history of relevant atopy.

          -  Subjects who had a history of relevant drug hypersensitivity (carbamazepine and

          -  related compounds).

          -  Subjects who had a history of alcoholism.

          -  Subjects who had a history of drug abuse.

          -  Subjects who consumed more than 28 units of alcohol a week.

          -  Subjects who had a significant infection or known inflammatory process on screening
             and/or admission.

          -  Subjects who had acute gastrointestinal symptoms at the time of screening and/or
             admission (e.g. nausea, vomiting, diarrhoea, heartburn).

          -  Subjects who had an acute infection such as influenza at the time of screening and/or
             admission.

          -  Subjects who had used prescription drugs within 4 weeks of first dosing.

          -  Subjects who had used over the counter medication, excluding routine vitamins but
             including mega dose vitamin therapy, within one week of dosing.

          -  Subjects who had used any investigational drug and/or participated in any clinical
             trial within 3 months of admission to this study.

          -  Subjects who had donated and/or received any blood or blood products within 3 months
             prior to screening.

          -  Subjects who were vegetarians, vegans and/or had medical dietary restrictions.

          -  Subjects who could not communicate reliably with the investigator.

          -  Subjects who were unlikely to co-operate with the requirements of the study.

          -  Subjects who were unwilling or unable to give written informed consent.

          -  Subjects who had previously received BIA 2-093.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Guy's Drug Research Unit</name>
      <address>
        <city>London</city>
        <zip>SE1 1YR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 20, 2014</study_first_submitted>
  <study_first_submitted_qc>June 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 24, 2014</study_first_posted>
  <results_first_submitted>November 28, 2014</results_first_submitted>
  <results_first_submitted_qc>December 19, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 7, 2015</results_first_posted>
  <last_update_submitted>December 19, 2014</last_update_submitted>
  <last_update_submitted_qc>December 19, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 7, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Epilepsy</keyword>
  <keyword>BIA 2-093</keyword>
  <keyword>Eslicarbazepine acetate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epilepsy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eslicarbazepine acetate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>PLC, Placebo</description>
        </group>
        <group group_id="P2">
          <title>Group 1 - 200 mg b.i.d.</title>
          <description>BIA 2-093 200mg (twice daily)</description>
        </group>
        <group group_id="P3">
          <title>Group 2 - 400 mg o.d.</title>
          <description>BIA 2-093, ESL, Eslicarbazepine 400mg</description>
        </group>
        <group group_id="P4">
          <title>Group 3 - 800 mg o.d.</title>
          <description>BIA 2-093, ESL, Eslicarbazepine 800mg</description>
        </group>
        <group group_id="P5">
          <title>Group 4 - 1200 mg o.d.</title>
          <description>BIA 2-093, ESL, Eslicarbazepine 1200mg</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>PLC, Placebo</description>
        </group>
        <group group_id="B2">
          <title>Group 1 - BIA 2-093 200 mg b.i.d.</title>
          <description>BIA 2-093, ESL, Eslicarbazepine acetate 200mg (twice daily)</description>
        </group>
        <group group_id="B3">
          <title>Group 2 - BIA 2-093 400 mg o.d.</title>
          <description>BIA 2-093, ESL, Eslicarbazepine acetate 400mg</description>
        </group>
        <group group_id="B4">
          <title>Group 3 - BIA 2-093 800 mg o.d.</title>
          <description>BIA 2-093, ESL, Eslicarbazepine acetate 800mg</description>
        </group>
        <group group_id="B5">
          <title>Group 4 - BIA 2-093 1200 mg o.d.</title>
          <description>BIA 2-093, ESL, Eslicarbazepine acetate 1200mg</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="6"/>
            <count group_id="B5" value="6"/>
            <count group_id="B6" value="32"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Cmax</title>
        <description>Cmax - Maximum observed plasma concentration</description>
        <time_frame>Day 1 and Day 8</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1 - BIA 2-093 200 mg b.i.d.</title>
            <description>BIA 2-093, ESL, Eslicarbazepine acetate 200mg (twice daily)</description>
          </group>
          <group group_id="O2">
            <title>Group 2 - BIA 2-093 400 mg o.d.</title>
            <description>BIA 2-093, ESL, Eslicarbazepine acetate 400mg</description>
          </group>
          <group group_id="O3">
            <title>Group 3 - BIA 2-093 800 mg o.d.</title>
            <description>BIA 2-093, ESL, Eslicarbazepine acetate 800mg</description>
          </group>
          <group group_id="O4">
            <title>Group 4 - BIA 2-093 1200 mg o.d.</title>
            <description>BIA 2-093, ESL, Eslicarbazepine acetate 1200mg</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax</title>
          <description>Cmax - Maximum observed plasma concentration</description>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cmax Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3086" spread="1342"/>
                    <measurement group_id="O2" value="7827" spread="1313"/>
                    <measurement group_id="O3" value="11074" spread="1919"/>
                    <measurement group_id="O4" value="16071" spread="2238"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmax Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6683" spread="1576"/>
                    <measurement group_id="O2" value="8824" spread="1411"/>
                    <measurement group_id="O3" value="18675" spread="2613"/>
                    <measurement group_id="O4" value="25457" spread="2746"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC0-τ</title>
        <description>AUC0-τ - Area under the plasma concentration time curve to last measurable time point
Day 1 - pre-dose, 30, 60, 90, 120, 180 minutes, 4, 6, 7, 8, 12, hours post final dose Day 8 - pre-dose, 30, 60, 90, 120, 180 minutes, 4, 6, 7, 8, 12, 24, 36, 48 and 72 hours post final dose</description>
        <time_frame>Day 1 - pre-dose, 30, 60, 90, 120, 180 minutes, 4, 6, 7, 8, 12, hours post final dose Day 8 - pre-dose, 30, 60, 90, 120, 180 minutes, 4, 6, 7, 8, 12, 24, 36, 48 and 72 hours post final dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1 - BIA 2-093 200 mg b.i.d.</title>
            <description>BIA 2-093, ESL, Eslicarbazepine acetate 200mg (twice daily)</description>
          </group>
          <group group_id="O2">
            <title>Group 2 - BIA 2-093 400 mg o.d.</title>
            <description>BIA 2-093, ESL, Eslicarbazepine acetate 400mg</description>
          </group>
          <group group_id="O3">
            <title>Group 3 - BIA 2-093 800 mg o.d.</title>
            <description>BIA 2-093, ESL, Eslicarbazepine acetate 800mg</description>
          </group>
          <group group_id="O4">
            <title>Group 4 - BIA 2-093 1200 mg o.d.</title>
            <description>BIA 2-093, ESL, Eslicarbazepine acetate 1200mg</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-τ</title>
          <description>AUC0-τ - Area under the plasma concentration time curve to last measurable time point
Day 1 - pre-dose, 30, 60, 90, 120, 180 minutes, 4, 6, 7, 8, 12, hours post final dose Day 8 - pre-dose, 30, 60, 90, 120, 180 minutes, 4, 6, 7, 8, 12, 24, 36, 48 and 72 hours post final dose</description>
          <units>ng.h/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AUC0-τ Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22163" spread="6216"/>
                    <measurement group_id="O2" value="96262" spread="17064"/>
                    <measurement group_id="O3" value="159492" spread="21695"/>
                    <measurement group_id="O4" value="250426" spread="27356"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC0-τ Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63140" spread="7997"/>
                    <measurement group_id="O2" value="126308" spread="14833"/>
                    <measurement group_id="O3" value="268384" spread="27683"/>
                    <measurement group_id="O4" value="423003" spread="45952"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Total Number of Adverse Events</title>
        <description>Total Number of Adverse Events.</description>
        <time_frame>up to 20 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1 - BIA 2-093 200 mg b.i.d.</title>
            <description>BIA 2-093, ESL, Eslicarbazepine acetate 200mg (twice daily)</description>
          </group>
          <group group_id="O2">
            <title>Group 2 - BIA 2-093 400 mg o.d.</title>
            <description>BIA 2-093, ESL, Eslicarbazepine acetate 400mg</description>
          </group>
          <group group_id="O3">
            <title>Group 3 - BIA 2-093 800 mg o.d.</title>
            <description>BIA 2-093, ESL, Eslicarbazepine acetate 800mg</description>
          </group>
          <group group_id="O4">
            <title>Group 4 - BIA 2-093 1200 mg o.d.</title>
            <description>BIA 2-093, ESL, Eslicarbazepine acetate 1200mg</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>PLC, Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Total Number of Adverse Events</title>
          <description>Total Number of Adverse Events.</description>
          <units>Total Number of AE</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All Adverse Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="12"/>
                    <measurement group_id="O5" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AE Considered Not Related to Treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AE Considered Possibly Related to Treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="12"/>
                    <measurement group_id="O5" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Adverse Events of Mild Severity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="12"/>
                    <measurement group_id="O5" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Adverse Events of Moderate Severity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>PLC, Placebo</description>
        </group>
        <group group_id="E2">
          <title>Group 1 - BIA 2-093 200 mg b.i.d.</title>
          <description>BIA 2-093, ESL, Eslicarbazepine acetate 200mg (twice daily)</description>
        </group>
        <group group_id="E3">
          <title>Group 2 - BIA 2-093 400 mg o.d.</title>
          <description>BIA 2-093, ESL, Eslicarbazepine acetate 400mg</description>
        </group>
        <group group_id="E4">
          <title>Group 3 - BIA 2-093 800 mg o.d.</title>
          <description>BIA 2-093, ESL, Eslicarbazepine acetate 800mg</description>
        </group>
        <group group_id="E5">
          <title>Group 4 - BIA 2-093 1200 mg o.d.</title>
          <description>BIA 2-093, ESL, Eslicarbazepine acetate 1200mg</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Gingival bleeding</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Mucositis NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic enzymes increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Herpes simplex</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Skeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Mouth dry</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Muscle contractions involuntary</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Concentration impaired</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Dreaming abnormal</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hallucination</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Upper resp tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Skin dry</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Head of Clinical Research</name_or_title>
      <organization>Bial – Portela &amp; Cª, S.A.</organization>
      <phone>+351 229 866 100</phone>
      <email>francisco.rocha@bial.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

